小剂量重组织型纤溶酶原激活剂与尿激酶、链激酶治疗急性心肌梗死疗效观察

目的:观察小剂量重组织型纤溶酶原激活剂、尿激酶和链激酶静脉溶栓治疗急性心肌梗死的疗效及安全性。方法:112例急性心肌梗死患者随机分为纤溶酶原激活剂组40例,尿激酶组30例,链激酶组42例。分别应用重组织型纤溶酶原激活剂50mg、尿激酶75万u、链激酶75万u于30min内静脉输入。结果:小剂量加速静脉溶栓心肌梗死相关血管再通率,重组织型纤溶酶原激活剂组80%,尿激酶组53.5%,链激酶组50%。重组织型纤溶酶原激活剂组与尿激酶组、链激酶组疗效比较P<0.05。3组溶栓后出血及5周病死率比较无明显差异。结论:小剂量重组织型纤溶酶原激活剂治疗急性心肌梗死的疗效明显优于小量尿激酶和链激酶,不良反应无明显差异。

Efficacy of intravenous thrombolytlc therapy with low dose recombinant tissue-type plasminogen activator, urokinase and streptokinase in patients with acute myocardial infarction

Objective To observe the effect and safety of intravenous thrombolytlc therapy with low dose recombinant tissue plasminogen activator (rt-PA) ,urokinase ,streptokinase in patients with acute myocardial infarction. Methods One hundred and twelve cases were randomly divided into rt-PA grong (40 cases), Urodinase group(30 cases) and streptokinase group(42 cases),which were treated with 50 mg rt-PA, 75ku urodinase snd 75ku streptokinase infusion within 30 mintues respectively. Results Rapid low dose intravenous thrombolytic therapy, the clinical reperfusion rates of infarctrelated in rt-PA 80%, significantly higher than that in urodinase group (53. 3%) and streptokinase group (50%) (P0. 05). Bleeding rate, the total 5-week mortality in 3 groups were not markedly different. Conclusion Low dose rt-PA is effective for acute myocardial infarction than urodinase and streptokinase. There is no significant difference in side effect.